Skip to main content

Table 1 Characteristics of patients before treatment of nivolumab

From: Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study

Variables n = 58
No. (%)
Sex
 Male 45 (78%)
 Female 13 (22%)
Age (years) (Median, Range) 66 (38–82)
ECOG performance status
 0 8 (14%)
 1 36 (62%)
 2 12 (21%)
 3 2 (3%)
Disease status
 Metastatic 43 (74%)
 Relapsed 15 (26%)
Primary site
 Gastric 49 (84%)
 Esophagogastric junction 9 (16%)
Histological type
 Intestinal type 34 (59%)
 Diffuse type 24 (41%)
HER-2 status
 Positive 13 (22%)
Site of metastases
 Lymph nodes 41 (72%)
 Peritoneum 27 (47%)
 Liver 20 (34%)
 Lung 12 (21%)
 Bone 9 (16%)
 Other 7 (12%)
Organs with metastasis
 1 17 (29%)
 2 24 (42%)
 3 13 (22%)
  ≥ 4 4 (7%)
Previous treatment regimens
 2 35 (60%)
 3 18 (31%)
  ≥ 4 5 (9%)
Previous therapies
 Pyrimidine analogs 56 (97%)
 Platinum 50 (86%)
 Taxane 55 (95%)
 Ramucirumab 48 (83%)
 Trastuzumab 11 (19%)
 Irinotecan 16 (28%)
Treatment period before nivolumab (months) 14.9 (4.9–64.6)
Immune-related adverse events
 Positive 10 (17%)